18 F-FDG PET/MRI for Diagnosis and Treatment Efficacy Evaluation of Spinal Sarcoidosis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38048521.
- Also identified by DOI 10.1097/RLU.0000000000004968.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Spinal cord sarcoidosis (SCS) is an uncommon disease with estimated incidence of 0.4% in patients with systemic sarcoidosis. Spinal cord sarcoidosis typically manifests late in the disease course and significantly contributes to patient morbidity. Therefore, early SCS diagnosis and prompt initiation of therapy are crucial. Herein, we report the case of a 51-year-old man with symptomatic SCS managed by 18 F-FDG PET/MRI, allowing diagnosis and treatment efficacy evaluation of spine involvement. We believe that the increasing clinical availability of hybrid PET/MRI devices will offer new opportunities for optimal management of patients with uncommon severe sarcoidosis localizations, such as nervous system.
Medical subject headings
- Fluorodeoxyglucose F18
- Sarcoidosis